




# Revista de Senología y Patología Mamaria

[www.elsevier.es/senologia](http://www.elsevier.es/senologia)



## ORIGINAL ARTICLE

# Effectiveness of ultrasound in the detection of axillary metastasis in patients with breast cancer without clinical evidence of axillary disease: Clinical impact

Gerardo Cuamani-Mitznahuatl<sup>a,b,\*</sup>, Héctor Isaac Rocha-González<sup>a</sup>,  
Christian Haydeé Flores-Balcázar<sup>c</sup>, Guadalupe Elizabeth Trejo-Durán<sup>a,d</sup>,  
María Elena Lara-Hernández<sup>b</sup>, Jaime de Jesús Ordoñez-Adán<sup>e</sup>,  
Jessica Gómez-Aguilar<sup>e</sup>, Rafael Vázquez-Romo<sup>b,\*</sup>

<sup>a</sup> Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, Mexico

<sup>b</sup> Servicio de Cirugía de Tumores Mamarios, Instituto Nacional de Cancerología, Tlalpan, Mexico City, Mexico

<sup>c</sup> Departamento de Radio oncología, Instituto Nacional de Cancerología, Tlalpan, Mexico City, Mexico

<sup>d</sup> Departamento de Braquiterapia, Instituto Nacional de Cancerología, Tlalpan, Mexico City, Mexico

<sup>e</sup> Centro Interdisciplinario de Ciencias de la Salud, Unidad Milpa Alta, Instituto Politécnico Nacional, Mexico City, Mexico

Received 5 June 2020; accepted 18 July 2020

### KEYWORDS

Axillary ultrasound;  
Breast cancer;  
Metastasis

### Abstract

**Introduction:** Preoperative ultrasound in patients with breast cancer without evidence of clinical axillary disease represents an attempt to reliably identify axillary lymph node metastasis. However, the usefulness of ultrasound for the detection of axillary disease should be evaluated.

**Materials and methods:** The study included a retrospective cohort of 826 patients with diagnosed invasive breast cancer, treated at the National Cancer Institute of Mexico, from 2014 to 2018. All patients underwent ipsilateral axillary ultrasound for staging purposes. Besides the descriptive analysis of the preoperative ultrasound, findings of the cohort were compared with their corresponding cytology and histopathology reports.

**Results:** Diagnostic index for axillary ultrasound was calculated as follows: 32.8% sensitivity, 82.5% specificity, 37.1% positive predictive value (PPV), 79.6% negative predictive value (NPV), 70.6% diagnostic accuracy, 1.86 positive likelihood ratio (LR+), and 0.81 negative likelihood ratio (LR-). Loss of fatty hilum was associated with a higher risk of axillary metastasis on the multivariate analysis (OR 3.645; 95% CI, 1.664–7.985,  $p < 0.001$ ).

\* Corresponding author.

E-mail addresses: [Cuamanigm@gmail.com](mailto:Cuamanigm@gmail.com) (G. Cuamani-Mitznahuatl), [vrrafa@yahoo.com.mx](mailto:vrrafa@yahoo.com.mx) (R. Vázquez-Romo).

<https://doi.org/10.1016/j.senol.2020.07.007>

0214-1582/© 2020 SESPM. Published by Elsevier España, S.L.U. All rights reserved.

## PALABRAS CLAVE

Ecografía axilar;  
Cáncer de mama;  
Metástasis

**Conclusions:** The utility of axillary ultrasound as a method of determining the nodal status prior to surgery in patients with breast cancer without clinical evidence of axillary disease was not demonstrated in this study.

© 2020 SESPM. Published by Elsevier España, S.L.U. All rights reserved.

## Efectividad de la ecografía en la detección de metástasis axilares en pacientes con cáncer de mama sin evidencia clínica de enfermedad axilar: impacto clínico

### Resumen

**Introducción:** La ecografía preoperatoria en pacientes con cáncer de mama sin evidencia de enfermedad clínica axilar representa un intento de identificar de manera confiable metástasis a ganglios linfáticos axilares. Sin embargo, se debe evaluar la utilidad de la ecografía para la detección de la enfermedad axilar.

**Material y métodos:** El estudio incluyó una cohorte retrospectiva de 826 pacientes con cáncer de mama invasivo diagnosticado en el Instituto Nacional de Cancerología de México, de 2014 a 2018. Todos los pacientes se sometieron a una ecografía axilar ipsilateral con fines de estadificación. Además del análisis descriptivo de la ecografía preoperatoria, los resultados de la cohorte se compararon con sus correspondientes informes de citología e histopatología.

**Resultados:** Los índices diagnósticos para la ecografía axilar fueron: 32,8% de sensibilidad, 82,5% de especificidad, 37,1% de valor predictivo positivo (VPP), 79,6% de valor predictivo negativo (VPN), 70,6% de precisión diagnóstica, 1,86 de razón de verosimilitud positiva ( $LR^+$ ) y 0,81 de razón de verosimilitud negativa ( $LR^-$ ). La pérdida de hilio graso se asoció con un mayor riesgo de metástasis axilares en el análisis multivariado (RM: 3.645; IC al 95%: 1.664-7.985;  $p < 0,001$ ).

**Conclusiones:** La utilidad de la ecografía axilar como método para determinar el estado ganglionar antes de la cirugía en pacientes con cáncer de mama sin evidencia clínica de enfermedad axilar no se demostró en este estudio.

© 2020 SESPM. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

## Introduction

Breast cancer has become the leading cause of cancer deaths in women, with 626,679 deaths registered in 2018 and 2 million new cases diagnosed worldwide according to the GLOBOCAN database.<sup>1</sup>

Since the risk of finding nodal metastasis in patients with non-palpable axillary disease is about 20–40%,<sup>2–4</sup> the comprehensive assessment of the axillary is mandatory, as it is one of the most important prognostic variables in the management of primary breast cancer; therefore, axillary ultrasound has emerged as an option to identify patients with risk of nodal involvement.<sup>3,5–7</sup> Ultrasound findings related to malignant lymph nodes include variations in echogenicity, size, shape or borders, absence of uniformity, alterations in cortical thickness, and loss of fatty hilum on grayscale evaluation. Doppler analysis of suspicious lymph nodes can show abnormalities of the vascular pattern.<sup>8</sup>

The ultrasound diagnostic accuracy for staging axillary lymph nodes in breast cancer has been published before.<sup>5–11</sup> The sensitivity and positive predicted value (PPV) usually varies from 40–86% and 66–70%, respectively. Ultrasound specificity is about 90–93%.<sup>5–11</sup> The sensitivity and specificity

of the axillary ultrasound findings associated with axillary lymph node metastasis reported in literature widely varies and this highlights the need to improve the criteria for the preoperative axillary evaluation of patients.<sup>6</sup>

Recently, the study Z0011 from the American College of Surgeons Oncology Group (ACOSOG) revealed practice-changing results, making the axillary lymph node dissection (ALND) an unnecessary procedure in patients with clinical T1-T2 tumors treated with breast-conserving therapy having less than three axillary lymph nodes with metastasis.<sup>12</sup> The AMAROS trial results showed radiotherapy as a preferred alternative to ALND in this subset of patients. These studies questioned the usefulness of axillary ultrasound and preoperative fine needle aspiration biopsy (FNAB) as a less invasive axillary approach,<sup>5,12</sup> and its utility is yet to be elucidated in Mexico.

Because in our country compiled data on the diagnostic accuracy of the ultrasound for pre-surgery evaluation of the axilla is scarce, this study analyzed the utility of the ultrasound as a tool for staging patients with newly diagnosed breast cancer and clinically negative axilla. The concordance among physical examination, axillary ultrasound, and cytology and histopathology studies was evaluated as well.

## Materials and methods

A total of 826 women diagnosed and treated at the National Cancer Institute in Mexico City between 2014 and 2018 met the inclusion criteria. The data were extracted from medical records. All patients were classified according to the TNM (tumor, node, and metastasis) staging system. The patients' demographic and clinical characteristics were recorded. The diagnostic approach included clinical evaluation. In addition, to the axillary ultrasound for all the patients through Aloka ProSound Alpha 7 equipment with 38 mm linear transducer and 13.3–3.61 MHz of the frequency range. Axillary ultrasound findings were classified either as "suspicious" or "non-suspicious" based on the cortical thickness, fatty hilum, and shape of lymph nodes. Only patients with suspicious ultrasound findings underwent pre-surgery FNAB. After breast surgery, malignant cell clusters larger than 0.2 mm in extracted lymph nodes were considered as macrometastases or pN1a disease. The histopathology results were the standard of truth. The study meets ethical consideration and was approved by the Research Committee as required by the National Cancer Institute (INCAN/CI/0622/18).

Descriptive statistics, sensitivity, specificity, PPV, NPV, FN, FP and accuracy were obtained. Chi-square tests were used to analyze the categorical data between the differences of ultrasound findings and the histopathology reports. Positive likelihood ratio and negative likelihood ratio were calculated; diagnostic OR was calculated with a 95% confidential interval (CI). A logistic regression model was performed to identify the association between suspicious sonographic characteristics and metastatic lymph nodes. The statistical significance level was set at  $p < 0.05$ . Statistical analysis was performed using the SPSS software V.22.

## Results

The study population consisted of 826 women diagnosed with invasive breast carcinoma and non-palpable axillary disease, treated between 2014 and 2018. Patients who underwent neoadjuvant chemotherapy are excluded. The majority were postmenopausal women (mean age was 56.9 years). Ductal invasive breast carcinoma was the most common histology in 81.9% of the patients; 53% of the tumors were staged as T2. Demographic and tumor characteristics are shown in Table 1.

One hundred and seventy-five patients (21.2%) had suspicious lymph nodes by ultrasound (Table 2). One hundred and ninety-eight (24%) of the 826 women had breast surgery and axillary management showed metastatic lymph nodes, as it was determined by the final axillary histology (Table 3). In addition, micrometastases (<2 mm) was reported in 37 cases (4.5%).

From the 175 patients with suspicious axillary ultrasound, 65 (37.2%) patients had subsequent metastatic disease on axillary histopathology, thus corresponding to true positive cases (TP), and 110 (62.8%) patients had an absence of metastasis on histopathology, thus are false-positive cases (FP). On the other hand, of the 651 patients with non-suspicious axillary ultrasound, 133 patients (20.4%) had a positive histopathology report, thus corresponding to false-negative cases (FN), and 518 (79.6%) patients had an

**Table 1** Clinical characteristics of the patients, and biological characteristics of the primary breast tumor.

Variable	<i>n</i>	(%)
Age (years)	56.9	(24–93)
<i>Histology</i>		
Duct	677	(81.9)
Lobullillar	59	(7.2)
Mixed	70	(8.5)
Other	20	(2.4)
<i>Tumor</i>		
T1	370	(44.8)
T2	438	(53.0)
T3	18	(2.2)
<i>Clinical stage</i>		
I	370	(44.8)
IIA	438	(53.0)
IIB	18	(2.2)

Data are presented as mean (maximum–minimum) or *n* (%).

absence of metastasis on histopathology, true negative cases (TN).

The axillary ultrasound findings were compared with their correspondent histopathology study. The positive likelihood ratio (LH+) was 1.86 and the negative likelihood ratio (LH–) was 1.23 (0.81). The diagnostic OR of the test was 2.28 with a 95% confidence interval (CI = 1586–3299). According to the results of OR, patients with metastatic disease on axillary histopathology are only 2.28 times more likely to have suspicious axillary ultrasound than those without metastatic disease on axillary histopathology. The likelihood ratios were graphed in the Fagan Nomogram to obtain the post-test probability (Fig. 1).

According to review of axillary ultrasound findings, were reported 177 (21.4%) patients with cortical thickening, 74 (8.9%) patients showed abnormalities in the fatty hilum, and 50 (6.0%) patients not preserved the shape of the lymph node. A total of 62 patients (7.5%) had lymph nodes cortical thickening and abnormalities in the fatty hilum, 38 (4.6%) patients had cortical thickening and not preserved the shape of the lymph node, and 26 (3.1%) patients had abnormalities in the fatty hilum and not preserved the shape of the lymph node. Finally, 18 (2.1%) patients reported triple aberration in the axillary ultrasound report.

The analysis of sensitivity, specificity, Predictive Positive Value (PPV), Negative Predictive Value (NPV) and Diagnostic Accuracy (DA) of sonographic characteristics is reported in Tables 4 and 5.

Loss of fatty hilum and focal cortical thickening can be associated with a higher risk of metastases lymph nodes: OR 5.214 with 95% CI = 2.595–10.474,  $p < 0.001$  and OR 2.001 with 95% CI = 1.094–3.662,  $p = 0.024$  respectively. For all other echographic criteria, the  $p$  value was not statistically significant ( $p > 0.05$ ).

But, in multivariate analysis of the suspicious sonographic characteristics of the axillary lymph nodes showed that only the loss of the fatty hilum could be associated with a higher risk of metastasis in lymph nodes: OR 3.645 with 95% CI = 1.664–7.985 ( $p < 0.001$ ).

**Table 2** Characteristics of axillary lymph nodes observed by ultrasound.

Variables	Sonographic characteristics					
	Suspicious of metastasis		No suspicious of metastasis		Total	
	<i>n</i>	(%)	<i>n</i>	(%)	<i>n</i>	(%)
<i>Axillary ultrasound</i>	175	(21.2)	651	(78.8)	826	(100)
<i>Cortical of lymph node</i>						
Diffuse cortical thickening	12	(1.5)	3	(0.3)	15	(1.8)
Focal cortical thickening	48	(5.8)	3	(0.4)	51	(6.2)
Simple cortical thickening	99	(12.0)	12	(1.5)	111	(13.4)
Without cortical thickening	16	(1.9)	633	(76.6)	649	(78.6)
Total	175	(21.2)	651	(78.8)	826	(100)
<i>Fatty hilum of the lymph node</i>						
Loss of the fatty hilum	35	(4.3)	0	(0)	35	(4.3)
Unconventionality of the fatty hilum	39	(4.7)	0	(0)	39	(4.7)
Normal fatty hilum	101	(12.2)	651	(78.8)	752	(91.0)
Total	175	(21.2)	651	(78.8)	826	(100)
<i>Lymph node shape</i>						
Not preserved	46	(5.6)	4	(0.5)	50	(6.1)
Conserved	129	(15.6)	647	(78.3)	778	(93.9)
Total	175	(21.2)	651	(78.8)	826	(100)

Data are presented as *n* (%).

**Table 3** Contingency table that summarizes data of the axillary ultrasound and the histopathological study of the axillary lymph node.

	Histopathological study		Total
	Positive	Negative	
<i>Axillary ultrasound</i>			
Suspicious of metastasis	65	110	175
No suspicious of metastasis	133	518	651
Total	198	628	826

Data are presented as *n*.


From the 175 patients with axillary ultrasound suspicious of metastasis, 156 patients underwent preoperative FNAB. The cytology results were negative in 103 patients (66.0%); the most common diagnoses in negative results were lymphoid hyperplasia, 7 (4.4%) failed procedures, and positive cytology in 46 patients (29.4%); from these, 41 had a positive histopathology. A correspondence of 30.8% was found between the axillary ultrasound and the cytology. Regarding the cytology study and the histopathology study, the correspondence was 86.9%. In addition, 6 patients who had a suspicious ultrasound and a positive FNAB for metastasis not had subsequent metastatic disease on histopathology.

In the axillary surgical approach, 669 patients underwent only sentinel lymph node biopsy (SLNB), 101 patients underwent SLNB and ALND, 19 cases due to a failed SLNB (2.4%), and 56 patients underwent immediate ALND. In our work, 198 patients (24%) had a positive histopathology report, but from these, only 33 patients had a pN2a–pN3a axillary disease.

The findings obtained by ultrasound were not related to the pN2a–pN3a axillary disease ( $p > 0.05$ ). From the 33 patients with pN2a–pN3a disease, all cases are preserved shape of lymph node, 6 cases presented unconventionality in the fatty hilum and in 14 cases reported cortical thickening. The diagnostic indices of axillary ultrasound and the cytological study shown in Table 6.

## Discussion

Axillary clinical examination is essential.<sup>13</sup> However, have limitations: significant disparity of explorers, inaccurate appraisal of axillary lymph nodes, and lower sensitivity to a greater amount of adipose tissue, which results in up to 40% of false negatives in the clinical axillar evaluation.<sup>14</sup> In our data, the prevalence of axillary lymph node metastasis was 24%, which places the National Cancer Institute of Mexico as one of the oncological centers with significant



**Figure 1** Fagan Nomogram. Positive likelihood ratio (yellow line) and negative likelihood ratio (red line) for the post-test probability of axillary ultrasound.

experience for axillary clinical examination, without leaving aside the need for strategies that complement it.

The diagnostic guidelines in breast cancer place the preoperative axillary ultrasound as part of the diagnostic approach. Patients with non-suspicious ultrasound benefit from SLNB, thus avoiding ALND, a surgery with high morbidity. On the other hand, axillary ultrasound guides FNAB

of suspicious axillary lymph nodes toward correct staging of the disease and adjustment of the treatment. However, studies on the diagnostic accuracy and clinical utility of axillary ultrasound have presented inconsistent results in literature.<sup>15,16</sup>

Several studies have reported sensitivity for the axillary ultrasound ranges anywhere from 7.4% to 95%, and the specificity from 44% to 100%, in the diagnosis for metastasis in the axillary lymph nodes.<sup>5,9-11,15</sup> In 2008, the sensitivity for the cohort of Cowher et al. was 18.2% and the specificity of 96.3%.<sup>17</sup> In our study, the sensitivity was 32.8%. The diagnostic accuracy of ultrasound was not enough to perform the diagnosis of metastasis in this group of patients. In this regard, the sensitivity and PPV of axillary ultrasound will not reach 100%, but there is certainly room for improvement. Identification of morphologic determinants of axillary nodal metastasis will improve the sensitivity and PPV of axillary ultrasound, thereby increasing the certainty of the selection of surgical treatment and avoid unnecessary procedures.

Data on the specificity of axillary ultrasound is scarce due to the fact that several studies exclude patients without ultrasonographic findings of suspicion for metastasis, whereas patients with neoadjuvant chemotherapy are not excluded.<sup>7,8</sup> In the present report, the specificity rendered a value of 82.5%.

In the present work, the positive predictive value of the axillary ultrasound was 37.1%. Consequently, this value did not allow confirming the presence of metastasis. However, the negative predictive value was 79.6%, which allowed us to consider a low probability for metastasis. In this sense, the hypothesis that SLNB could be omitted in patients with non-suspicious axillary ultrasound is important. The most recent data show that most of these patients will have low burden of tumor disease in the axillary lymph nodes in case of metastasis.<sup>18-20</sup> The underlying reason for the diagnostic accuracy of the ultrasound (70.6%) in our data was mostly by the high negative predictive value.

False-positive cases of the axillary ultrasound were high percentage (62.8%). In addition, from patients submitted to FNAB due to a suspicious ultrasound, only 26.3% were positive for metastasis. These results show the high number of unnecessary procedures, the greater care that must be taken in the preoperative evaluation by ultrasound, and in the selection of patients who are chosen for FNAB, since all patients will be evaluated by SLNB and, if necessary, by

**Table 4** Diagnostic indices of the alteration of each one of the characteristics of the axillary lymph nodes obtained by ultrasound.

	Evaluation of the criteria of the ultrasound study				
	Sen	Spe	PPV	NPV	DA
Diffuse cortical thickening	4.1	98.3	40.0	78.6	77.7
Focal cortical thickening	11.5	93.9	35.3	78.6	75.4
Simple cortical thickening	20.1	87.0	31.5	78.6	71.7
Loss of the fatty hilum	11.1	97.7	60.0	77.7	76.9
Unconventionality of the fatty hilum	5.1	95.1	23.1	77.7	75.0
Not preserved shape	11.6	95.5	44.0	77.3	75.3

Data are presented as %.

Sensitivity (Sen), Specificity (Spe), Predictive Positive Value (PPV), Negative Predictive Value (NPV) and Diagnostic Accuracy (DA).

Please cite this article in press as: Cuamani-Mitznahuatl G, et al. Effectiveness of ultrasound in the detection of axillary metastasis in patients with breast cancer without clinical evidence of axillary disease: Clinical impact. Rev Senol Patol Mamar. 2020. <https://doi.org/10.1016/j.senol.2020.07.007>

**Table 5** Diagnostic indices of the alteration of each one of the characteristics of the axillary lymph nodes obtained by ultrasound.

	Evaluation criteria of the axillary ultrasound study						
	Cortical	Hilium	Shape	Cortical + Hilium	Cortical + Shape	Hilium + Shape	Hilium + Shape + Cortical
Sen	29.8	15.2	11.6	14.8	10.2	8.00	6.50
Spe	81.2	93.0	95.5	92.8	95.6	97.9	98.2
PPV	33.3	40.5	44.0	37.1	39.5	55.3	50.0
NPV	78.6	77.7	77.3	79.3	79.3	78.0	79.5
DA	68.9	74.3	75.3	75.5	77.0	77.2	78.6

Data are presented as %.

Sensitivity (Sen), Specificity (Spe), Predictive Positive Value (PPV), Negative Predictive Value (NPV) and Diagnostic Accuracy (DA).

**Table 6** Diagnostic indices of axillary ultrasound and fine needle aspiration biopsy for the diagnostic of axillary metastasis in patients with breast cancer.

Diagnostic index	Diagnostic indices of axillary ultrasound and FNAB	
	Axillary ultrasound	Fine needle aspiration
Sensitivity	32.8	74.1
Specificity	82.5	93.7
Positive predictive value	37.1	87.0
Negative predictive value	79.6	86.4
Diagnostic accuracy	70.6	86.6

Data are presented as %.

ALND. The importance of the ultrasound findings with high sensitivity should be emphasized to bring patients with the extensive axillary disease to FNAB, selecting those who will surely require ALND and in whom SLNB could be omitted, avoiding a double surgical procedure, a greater impact on costs, and a longer hospital stay.<sup>5,21</sup>

The clinical impact of a diagnostic test not reported in the majority of the studies that evaluate axillary ultrasound. In our work, we obtained a positive likelihood ratio of 1.86 and, a negative likelihood ratio of 1.23 (0.81). Thus, the clinical utility of the ultrasound alone is insufficient for staging of the axillary lymph nodes.<sup>20,22</sup> Besides, the value of our OR was 2.28, clinically effectiveness diagnostic tests report OR > 20.<sup>19</sup> Finally, according to the number necessary to diagnose (NND), must be done 7 axillary ultrasounds to obtain an accurate diagnosis of axillary metastasis.

Whitman et al. reported that a lymph node size greater than 2 cm was associated with a higher probability of metastasis. However, in 2013, More et al. reported in a work with 110 women a greater size in axillary nodes without metastasis than in those with metastasis. The lymph node size was classified as a finding with low sensitivity for the diagnosis of metastasis in axillary lymph nodes<sup>7,23,24</sup>; probably for this reason, the size of axillary lymph nodes was not reported in the axillary ultrasound reports.

The aberrations in morphological characteristics are related to lymph node alteration.<sup>10</sup> Several studies cite that the earliest finding in lymph nodes that could be related to metastasis is the cortical thickening with more than 2 mm.<sup>7,14,25</sup> In our work, cortical morphologic changes not were associated with axillary disease.

Nori et al. concluded that the most important morphological finding for lymph node metastasis was the loss of the fatty hilum, even with a better accuracy than cortical thickening (83.3% vs. 35%),<sup>10,24,26</sup> finding that concordance with our study. The unconventionality of the fatty hilum was related with lymphoid hyperplasia. Loss of fatty hilum was associated with a higher risk of axillary metastasis and is the only ultrasound finding of high PPV for the diagnosis of axillary metastasis in our cohort. This indicates that replacement of the fatty hilum may be an effective indicator of axillary metastasis. However, at the time evaluate combined with more sonographic findings, the loss of the fatty hilum lowers accuracy diagnostic.

In 2006, Álvarez et al. reported, 60.9% sensitivity using size criteria compared with 43.9% using morphologic criterion, proposing that the diagnostic accuracy improves when a morphological criterion is used in addition to size.<sup>9</sup> Housami et al. determined that there was no difference in sensitivity using only size, morphological criteria, or both (79.6 vs. 79.6,  $p=0.99$ ).<sup>27</sup> In our work, 20 from 33 patients (60.6%) who presented the loss of the fatty hilum had axillary metastasis. In our work, two or more morphological findings did not improve the diagnostic indices.

To increase the diagnostic accuracy of the ultrasound, FNAB is used; however, operator experience remains a crucial factor, and the results could vary according to quality of the equipment and the sharpness of the images. Therefore, it is suggested that the biopsy should be taken in several identified suspicious areas, in addition to having a cytologist who approved the quality of the samples.<sup>28-30</sup> In this study, we report a diagnostic concordance of 26.2% between the ultrasound and the cytological study, concluding that a

suspicious axillary ultrasound is not a predictor of positive cytology.

Results of the cytological study should be taken into account to decrease the number of false negatives, failed procedures, or inadequate results. The use of core needle biopsy (CNB) can be considered superior to FNAB for the CNB has reported a higher sensitivity and a lower number of repeated biopsies, although a higher number of complications has been reported; morbidity can be reduced with trained human resources to perform the procedure.<sup>5,27,31</sup>

The global acceptance of the ACOSOG Z0011 study since its publication has influenced the decisions regarding the surgical treatment of the axilla. In our work, 97.8% of patients had T1-T2 lesions, with non-palpable axillary disease. The results obtained in this study make it possible to propose the following change in the axillary ultrasound approach: from using it in the diagnosis of all patients with axillary metastasis to only in the patients with a high burden of tumor disease in the axilla, because the use of FNAB as an indicator of ALND can increase its use up to 20.8%.<sup>4,5,12,32</sup>

Limitations to our retrospective study include that some ultrasonographic findings of axillary lymph nodes were not reported in clinical records. The study highlights the need to prospectively identify standard criteria to evaluate the axillary lymph nodes

## Conclusion

Axillary ultrasound is an accessible study. However, its utility as a method of determining the nodal status before surgery in patients with breast cancer without clinical evidence of axillary disease in the National Cancer Institute of Mexico was not demonstrated in this study due to low sensibility and clinical utility. It is recommended taking into account only ultrasonographic findings of axillary lymph nodes with high PPV, in an attempt to try increase the utility of the study, and decrease unnecessary procedures.

## Authors' contributions

Gerardo Cuamani Mitznahuatl and Rafael Vázquez Romo were the principal investigators and contributed to the conception and design of the study. GCM, RVR and CHFB prepared the main text, and the tables and figure with help of HIRG, GETD and MELH. JJOA and JGA were collaborated for collection of clinical data. All authors contributed to the content. All authors read and approved the final manuscript.

## Conflict of interest

The authors declare that they have no conflict of interest.

## Acknowledgments

The authors would like to thank Mammary Tumors Department and Clinical Research Assistant of the Instituto Nacional de Cancerología of Mexico and the Escuela Superior de Medicina del Instituto Politécnico Nacional, Cuamani Mitznahuatl Gerardo is a Masters student and Conacyt

fellowship from Programa de Ciencias de la Salud, Instituto Politécnico Nacional.

## References

1. World Health Organization. <https://www.uicc.org/news/new-global-cancer-data-globocan-2018> [accessed 15.10.19].
2. Orhan Ü, Demet KÇ, Zehra H, Enver I. Axillary metastasis in clinically node-negative breast cancer. *J Egypt Natl Cancer Inst.* 2018;30:159–63.
3. Almerey T, Villacreses D, Li Z, Patel B, McDonough M, Gibson T, et al. Value of axillary ultrasound after negative axillary MRI for evaluating nodal status in high-risk breast cancer. *J Am Coll Surg.* 2019;228:792–7.
4. Bae MS, Shin SU, Song SE, Ryu HS, Han W, Moon WK. Association between US features of primary tumor and axillary lymph node metastasis in patients with clinical T1-T2N0 breast cancer. *Acta Radiol.* 2018;59:402–8.
5. Balasubramanian I, Fleming CA, Corrigan MA, Redmond HP, Kerin MJ, Lowery AJ. Meta-analysis of the diagnostic accuracy of ultrasound-guided fine-needle aspiration and core needle biopsy in diagnosing axillary lymph node metastasis. *Br J Surg.* 2018;105:1244–53.
6. Nwaogu IY, Yan Y, Appleton CM, Cyr AE, Margenthaler JA. Predictors of false negative axillary ultrasound in breast cancer. *J Surg Res.* 2015;198:351–4.
7. Elmore LC, Appleton CM, Zhou G, Margenthaler JA. Axillary ultrasound in patients with clinically node-negative breast cancer: which features are predictive of disease? *J Surg Res.* 2013;184:234–40.
8. Whitman GJ, Tracy JL, Adejolu M, Krishnamurthy S, Sheppard D. Lymph node sonography. *Ultrasound Clin.* 2011;6:369–80.
9. Alvarez S, Añorbe E, Alcorta P, López F, Alonso I, Cortés J. Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review. *Am J Roentgenol.* 2006;186:1342–8.
10. Goel G, Janaki PD, Smitha NV, Anupama R, Sundaram PS, Nataraj YS, et al. Role of axillary ultrasound fine needle aspiration cytology and sentinel lymph node biopsy in clinically N0 breast cancer. *Indian J Surg Oncol.* 2016;7:407–12.
11. Park VY, Kim EK, Moon HJ, Yoon JH, Kim MJ. Value of ultrasound-guided fine needle aspiration in diagnosing axillary lymph node recurrence after breast cancer surgery. *Am J Surg.* 2018;2016:969–73.
12. Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. *Lancet Oncol.* 2014;15:1303–10.
13. Cardenas SJ, Baragallo RJE, Bautista PV, Cervantes SG, Erazo V-SAA, Flores BCH. Consenso Mexicano sobre diagnóstico y tratamiento del cáncer mamario. 7a revisión. México: Elsevier; 2017. p. 5–13.
14. McCartan D, Stempel M, Eaton A, Morrow M, Pilewskie M. Impact of body mass index on clinical axillary nodal assessment in breast cancer patients. *Ann Surg Oncol.* 2016;23:3324–9.
15. Hankó-Bauer O, Podoleanu C, Georgescu R, Stolnicu S. The Accuracy of the preoperative axillary ultrasound examination in predicting the status of the sentinel lymph node involvement in patients with infiltrating breast carcinoma. *Chirurgia.* 2019;114:384–91.
16. Sharma N, Cox K. Axillary nodal staging with contrast-enhanced ultrasound. *Curr Breast Cancer Rep.* 2017;9:259–63.
17. Cowher MS, Erb KM, Poller W, Julian TB. Correlation of the use of axillary ultrasound and lymph node needle biopsy with surgical lymph node pathology in patients with invasive breast cancer. *Am J Surg.* 2008;196:756–9.

18. Jozsa F, Ahmed M, Baker R, Douek M. Is sentinel node biopsy necessary in the radiologically negative axilla in breast cancer? *Breast Cancer Res Treat.* 2019;177:1–4.
19. Argimon PJM, Jiménez VJ. *Métodos de investigación clínica y epidemiológica.* 4a edición. España: Elsevier; 2017. p. 339–44.
20. Bravo GS, Cruz QJP. Estudios de exactitud diagnóstica: herramientas para su Interpretación. *Revista Chilena de Radiología.* 2015;21:158–64.
21. Davis JT, Brill YM, Simmons S, Sachleben BC, Cibull ML, McGrath P, et al. Ultrasound-guided fine-needle aspiration of clinically negative lymph nodes versus sentinel node mapping in patients at high risk for axillary metastasis. *Ann Surg Oncol.* 2006;13:1545–52.
22. Fuente AS, Molina VM. Likelihood ratio (razón de verosimilitud): definición y aplicación en Radiología. *Revista Argentina de Radiología.* 2017;81:204–8.
23. Nori J, Vanzi E, Bazzocchi M, Bufalini FN, Distante V, Branconi F, et al. Role of axillary ultrasound examination in the selection of breast cancer patients for sentinel node biopsy. *Am J Surg.* 2007;193:16–20.
24. Bedi DG, Krishnamurthy R, Krishnamurthy S, Edeiken BS, Le-Petross H, Fornage BD, et al. Cortical morphologic features of axillary lymph nodes as a predictor of metastasis in breast cancer: in vitro sonographic study. *Am J Roentgenol.* 2008;191:646–52.
25. Mainiero MB, Cinelli CM, Koelliker SL, Graves TA, Chung MA. Axillary ultrasound and fine-needle aspiration in the preoperative evaluation of the breast cancer patient: an algorithm based on tumor size and lymph node appearance. *Am J Roentgenol.* 2010;195:1261–7.
26. Abe H, Schmidt RA, Kulkarni K, Sennett CA, Mueller JS, Newstead GM. Axillary lymph nodes suspicious for breast cancer metastasis: sampling with US-guided 14-gauge core-needle biopsy-clinical experience in 100 patients. *Radiology.* 2012;250:41–9.
27. Houssami N, Ciatto S, Turner RM, Cody HS 3rd, Macaskill P. Pre-operative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer. *Ann Surg.* 2011;254:243–51.
28. Aguilar CLO, Guzmán NL, Barragán PDL, Lázaro LJM, Cravioto MRA, Martínez VNL, et al. In: *Manual PADE con abordaje integrado para el diagnóstico temprano clínico y radiológico del cáncer mamario.* Permanyer México. 2013.
29. Nowikiewicz T, Nowak Ad, Wiśniewska M, Wiśniewski M, Nowikiewicz M, Zegarski W. Analysis of the causes of false negative and false positive results of preoperative axillary ultrasound in patients with early breast cancer – a single-centre study. *Współczesna Onkologia.* 2018;22:247–51.
30. Bhandari A, Xia E, Wang Y, Sindan N, Kc R, Guan Y, et al. Impact of sentinel lymph node biopsy in newly diagnosed invasive breast cancer patients with suspicious node: a comparative accuracy survey of fine-needle aspiration biopsy versus core-needle biopsy. *Am J Transl Res.* 2018;10:1860–73.
31. Van Wely BJ, de Wilt JH, Francissen C, Teerenstra S, Strobbe LJ. Meta-analysis of ultrasound-guided biopsy of suspicious axillary lymph nodes in the selection of patients with extensive axillary tumour burden in breast cancer. *Br J Surg.* 2015;102:159–68.
32. Giuliano AE, McCall LM, Beitsch PD, Whitworth PW, Morrow PW, Blumencranz PW, et al. ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node. *J Clin Oncol.* 2010;28:18.